Related Experiment Video
Updated: Sep 28, 2025

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Nada Bejar1, Trinh T Tat1, Daniel L Kiss2,3,4,5
1Center for RNA Therapeutics, Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave, R10‑113, Houston, 77030, TX, USA.
Purpose Of Review:
RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella.
Recent Findings:
RNA therapeutics are designed to regulate gene expression in a transient manner. For example, depending upon the strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. RNA therapies include antisense nucleotides, microRNAs and small interfering RNAs, RNA aptamers, and messenger RNAs. Further, we discuss the mechanism(s) by which different RNA therapies either reduce or increase the expression of their targets. We review the RNA therapeutics approved (and those in trials) to treat cardiovascular indications. RNA-based therapeutics are a new, rapidly growing class of drugs that will offer new alternatives for an increasing array of cardiovascular conditions.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Coronary Artery Disease V: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

